Removal of Ticagrelor by Hemoadsorption with the HA380 Cartridge.

2025-02-18

Furukawa, Taku

Lankadeva, Yugeesh R

Baldwin, Ian C

Ow, Pei Chen Connie

Hood, Sally

Daali, Youssef

Schneider, Antoine

Decosterd, Laurent A

May, Clive N

Bellomo, Rinaldo

Antiplatelet drug

HA380 Jafron cartridge

Hemoadsorption

Ticagrelor

News

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1159/000544770

Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose. Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 h. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points. The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 min, which declined rapidly to 2.66% (SD 18.5) at 120 min and 0.48% (SD 17.0) at 240 min. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 min. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 min to near zero at 120 and 240 min. HA with the HA380 cartridge can achieve an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.

link

Blood purification 2025-02-18

Blood purification

1421-9735